Rosiglitazone for HIV-1 lipoatrophy [3] (multiple letters)

Lancet

Volumn 363, Issue 9423, 2004, Pages 1828-1829

  Cavalcanti, Rodrigo B ^a   Raboud, Janet ^b   Kain, Kevin C ^a   Walmsley, Sharon ^a   Carr, Andrew ^c   Wand, Handan ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST VINCENT S HOSPITAL   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; ZIDOVUDINE;

CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LETTER; LIPOATROPHY; PRIORITY JOURNAL;

EID: 2542550407     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16318-6     Document Type: Letter

References (4)

1. A Carr C Workman D Carey No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial Lancet 363 2004 429 438
2. GJ Moyle C Baldwin B Langroudi S Mandalia BG Gazzard A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy J Acquir Immune Defic Syndr 33 2003 22 28
3. PW Mallon J Miller DA Cooper A Carr Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy AIDS 17 2003 971 979
4. G Moyle J Sutinen Managing HIV lipoatrophy Lancet 363 2004 412 414